HERE0:4

Merck

Merck Raises Earnings Outlook
finchannel.com

The company announced the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of JANUVIA (sitagliptin), a medicine that helps lower blood sugar levels in adults with type 2 diabetes, achieved its primary endpoint of non-inferiority for …

2
Like
Save
Merck Announces First-Quarter 2015 Financial Results
www.fiercepharma.com

The company announced the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of JANUVIA (sitagliptin), a medicine that helps lower blood sugar levels in adults with type 2 diabetes, achieved its primary endpoint of non-inferiority for …

11
Like
Save
Merck & Co. (MRK) Kenneth C. Frazier on Q1 2015 Results – Earnings Call …
seekingalpha.com

The 5% impact from exchange is net of a 2% hedging benefit we realized in the quarter. Our sales decline reflects approximately $700 …. Yesterday we announced the results from our TECOS study in patients with type-two diabetes. This study compared …

15
Like
Save